Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer

doi:10.5306/wjco.v7.i6.425

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 6

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9367)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

522

WORD

414

HTML

4065

Figures (1-2)

572

Tables (1-2)

512

Sum=6085

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1236

Download

2046

Sum=3282

Dec 10, 2016 (publication date) through Feb 23, 2026

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Basic Study

World J Clin Oncol. Dec 10, 2016; 7(6): 425-432
Published online Dec 10, 2016. doi: 10.5306/wjco.v7.i6.425

Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer

Nele Van Der Steen, Christophe Deben, Vanessa Deschoolmeester, An Wouters, Filip Lardon, Christian Rolfo, Paul Germonpré, Elisa Giovannetti, Godefridus J Peters, Patrick Pauwels

Nele Van Der Steen, Christophe Deben, Vanessa Deschoolmeester, An Wouters, Filip Lardon, Christian Rolfo, Paul Germonpré, Patrick Pauwels, Center for Oncological Research, University of Antwerp, 2610 Wilrijk, Belgium

Nele Van Der Steen, Christophe Deben, Vanessa Deschoolmeester, Patrick Pauwels, Department of Pathology, Antwerp University Hospital, 2650 Edegem, Belgium

Nele Van Der Steen, Elisa Giovannetti, Godefridus J Peters, Department of Medical Oncology, VU University Medical Center, 1081 HV Amsterdam, The Netherlands

Christian Rolfo, Department of Oncology, Antwerp University Hospital, 2650 Edegem, Belgium

Paul Germonpré, Department of Pneumology, AZ Maria Middelares, 9000 Ghent, Belgium

Elisa Giovannetti, Cancer Pharmacology Lab, AIRC Start-Up Unit, University of Pisa, 56124 Pisa, Italy

Author contributions: All the authors contributed to the manuscript.

Supported by Institute for Innovation, Science and Technology Flanders (IWT), NO: 121114.

Institutional review board statement: Not applicable.

Conflict-of-interest statement: To the best of our knowledge, no conflict of interest exists.

Correspondence to: Elisa Giovannetti, MD, PhD, Department of Medical Oncology, VU University Medical Center, room 1.53, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands. elisa.giovannetti@gmail.com

Telephone: +31-20-4442630

Received: June 20, 2016
Peer-review started: June 20, 2016
First decision: August 11, 2016
Revised: September 29, 2016
Accepted: October 25, 2016
Article in press: October 27, 2016
Published online: December 10, 2016
Processing time: 162 Days and 15.5 Hours

Core Tip

Core tip: Targeted therapies are a valuable treatment option in non-small cell lung cancer. Several therapies have now been approved like erlotinib and gefitinib for epidermal growth factor receptor - mutant patients and crizotinib for Anaplastic Lymphoma Kinase-rearranged patients. However, resistance against these therapies eventually occurs. Combination therapy might be able to overcome or delay this resistance. Here we investigate the combination of the cMET inhibitor crizotinib with cisplatin in a panel of non-small cell lung cancer (NSCLC) cell lines with different histological and genetic backgrounds. We show that this leads to strong antagonism in all of the used cell lines. Furthermore we also link these results to the earlier in vitro and clinical results of the combination of erlotinib/gefitinib with cisplatin based chemotherapy in NSCLC.